相关实验视频

Updated: May 17, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

内分泌学医务人员对利拉格卢提德和塞马格卢提德的知识,态度和实践

Bingling Liu¹, Xueyi Wu², Xiao Zou¹

¹Department of Endocrinology, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO. 1 People's Hospital, No. 48, South Taling Road, Jiujiang, 332000, Jiangxi, China.

Scientific reports

|April 4, 2025

概括

内分泌学工作人员在知识,态度和实践中存在关于西马格卢提德和利拉格卢提德的差距. 改善这些领域对于使用这些GLP-1受体激动剂有效治疗代谢障碍至关重要.

科学领域:

代谢障碍和内分泌学
药理学和治疗学药理学和治疗学

背景情况:

塞马格卢提德和利拉格卢提德是代谢障碍的关键治疗方法,具有明显的临床特征.
内分泌学医务人员在这些药物的使用中发挥着至关重要的作用.
现有的文献缺乏有关医疗保健专业人员对这些特定药物的知识,态度和实践 (KAP) 的全面数据.

研究的目的:

评估内分泌学医务人员对半黄和黄的知识,态度和实践 (KAP).
确定影响KAP的因素,并探索知识,态度和实践之间的相互关系.

主要方法:

一项横截面研究对江江第一人民医院的265名内分泌医务人员进行了跨截面研究.
参与者填写了一份自我管理的问卷,以评估他们对塞马格卢提德和利拉格卢提德的KAP.
使用结构方程建模 (SEM) 来分析KAP组件之间的关系.

主要成果:

平均KAP分数表明参与者的缺陷:知识 (11.77/16),态度 (39.30/50),以及实践 (27.70/35).
SEM分析显示,知识对态度 (β=0.976,P<0.001) 和实践 (β=1.289,P<0.001) 都产生了重大影响.
还发现态度对实践有显著的影响 (β=0.627,P<0.001).

结论:

在内分泌学医务人员的知识,态度和实践中,存在严重的缺陷,这些缺陷涉及西马格卢提德和利拉格卢提德.
有针对性的教育干预和战略是必要的,以提高管理这些代谢障碍治疗的专业技能.
提高知识和态度对于优化与GLP-1受体激动剂相关的临床实践至关重要.

关键词:

横截面研究横截面研究内分泌部门内分泌部门知识,态度,以及实践.利拉格卢提德 (Liraglutide) 是一种类药物.医务人员医疗人员塞马格卢提德 (semaglutide) 是一种类型的

更多相关视频

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...